CHRISTIAN O HENRY, a director at $WVE, sold 10,500 shares of the company on 03-20-2025 for an estimated $102,574. We received data on the trade from a recent SEC filing. This was a sale of approximately 39.5% of their shares of this class of stock. Following this trade, they now own 16,115 shares of this class of $WVE stock.
$WVE Insider Trading Activity
$WVE insiders have traded $WVE stock on the open market 12 times in the past 6 months. Of those trades, 1 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $WVE stock by insiders over the last 6 months:
- PLC GSK purchased 2,791,930 shares for an estimated $22,335,440
- PAUL BOLNO (President and CEO) has made 0 purchases and 4 sales selling 360,733 shares for an estimated $4,458,350.
- CHRIS FRANCIS (See Remarks) has made 0 purchases and 5 sales selling 244,836 shares for an estimated $3,431,050.
- KYLE MORAN (Chief Financial Officer) sold 17,146 shares for an estimated $154,314
- CHRISTIAN O HENRY sold 10,500 shares for an estimated $102,574
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$WVE Hedge Fund Activity
We have seen 115 institutional investors add shares of $WVE stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARTAL GROUP S.A. removed 4,566,251 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $37,443,258
- BLACKROCK, INC. added 2,061,740 shares (+28.2%) to their portfolio in Q4 2024, for an estimated $25,503,723
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,972,262 shares (+63.1%) to their portfolio in Q4 2024, for an estimated $24,396,880
- SIREN, L.L.C. removed 1,970,681 shares (-34.4%) from their portfolio in Q4 2024, for an estimated $24,377,323
- MAVERICK CAPITAL LTD removed 1,786,278 shares (-17.8%) from their portfolio in Q4 2024, for an estimated $22,096,258
- LOOMIS SAYLES & CO L P added 1,660,866 shares (+inf%) to their portfolio in Q4 2024, for an estimated $20,544,912
- TAKEDA PHARMACEUTICAL CO LTD removed 1,346,892 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $16,661,054
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$WVE Analyst Ratings
Wall Street analysts have issued reports on $WVE in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 10/17/2024
- Wells Fargo issued a "Overweight" rating on 10/17/2024
- Raymond James issued a "Strong Buy" rating on 10/16/2024
- B. Riley issued a "Buy" rating on 10/03/2024
To track analyst ratings and price targets for $WVE, check out Quiver Quantitative's $WVE forecast page.
$WVE Price Targets
Multiple analysts have issued price targets for $WVE recently. We have seen 7 analysts offer price targets for $WVE in the last 6 months, with a median target of $22.0.
Here are some recent targets:
- Joon Leen from Truist Financial set a target price of $36.0 on 11/12/2024
- Luca Issi from RBC Capital set a target price of $15.0 on 10/21/2024
- Tiago Fauth from Wells Fargo set a target price of $22.0 on 10/17/2024
- Strong Buy from Raymond James set a target price of $22.0 on 10/16/2024
- Joseph Schwartz from Leerink Partners set a target price of $22.0 on 10/16/2024
- Madison El-Saadi from B.Riley Financial set a target price of $19.0 on 10/03/2024
- Salim Syed from Mizuho Securities set a target price of $19.0 on 09/25/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
